Sugi Predict

Sugi Predict / Targets / IL23R

IL23R

Interleukin-23 receptor · Q5VWK5 · IL23R on Sugi Atlas →

10,684 patent compounds predicted against IL23R, 7,279 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL11796453 SCHEMBL11796453 0.68 20/20
SCHEMBL11331799 SCHEMBL11331799 0.67 20/20
SCHEMBL11331814 SCHEMBL11331814 0.67 20/20
SCHEMBL10046407 SCHEMBL10046407 0.58 20/20
SCHEMBL10052936 SCHEMBL10052936 0.53 20/20
SCHEMBL10046332 SCHEMBL10046332 0.52 20/20
SCHEMBL11522373 SCHEMBL11522373 0.68 19/20
SCHEMBL11420342 SCHEMBL11420342 0.66 19/20
SCHEMBL11420357 SCHEMBL11420357 0.66 19/20
SCHEMBL11435178 SCHEMBL11435178 0.66 19/20
SCHEMBL11490971 SCHEMBL11490971 0.66 19/20
SCHEMBL11490981 SCHEMBL11490981 0.66 19/20
SCHEMBL11596064 SCHEMBL11596064 0.66 19/20
SCHEMBL11596073 SCHEMBL11596073 0.66 19/20
SCHEMBL7151611 SCHEMBL7151611 0.62 19/20
SCHEMBL11418008 SCHEMBL11418008 0.62 19/20
SCHEMBL11418049 SCHEMBL11418049 0.62 19/20
SCHEMBL11420692 SCHEMBL11420692 0.62 19/20
SCHEMBL11420700 SCHEMBL11420700 0.62 19/20
SCHEMBL11422620 SCHEMBL11422620 0.62 19/20

Clinical trials — most relevant to IL23R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics PHASE4RECRUITING
Risankizumab Long-term Remission Study PHASE4COMPLETED
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions PHASE4COMPLETED
The Effects of Dupilumab on Allergic Contact Dermatitis PHASE4ACTIVE_NOT_RECRUITING
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy PHASE3COMPLETED
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) PHASE3COMPLETED
Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis PHASE3COMPLETED
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis PHASE3ACTIVE_NOT_RECRUITING
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis PHASE2COMPLETED
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus PHASE2COMPLETED
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis PHASE2COMPLETED
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease PHASE2COMPLETED
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP) PHASE2COMPLETED
Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease PHASE2COMPLETED
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis PHASE1COMPLETED
A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis PHASE1COMPLETED
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab. EARLY_PHASE1WITHDRAWN
Relation of IL23R and IL17A Gene Polymorphisms Plus Serum Levels of IL23 and IL17A to Rheumatoid Arthritis Susceptibility and Activity nanNOT_YET_RECRUITING
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis nanRECRUITING
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice nanACTIVE_NOT_RECRUITING
Gene Expression in Chronic Venous Leg Ulcers nanUNKNOWN
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients nanUNKNOWN
Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder nanUNKNOWN
IL-11 in the Development of Multiple Sclerosis nanUNKNOWN
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD) nanNOT_YET_RECRUITING
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease nanCOMPLETED
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease nanRECRUITING
Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis nanCOMPLETED
Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a IL23R binder may also engage these)

ProteinNameSimilarity
Q8K4B4 — 1.000 Q8K4B4 →
P16872 — 0.996 P16872 →
Q9MYL0 — 0.994 Q9MYL0 →
Q28172 — 0.993 Q28172 →
A5HJM1 — 0.993 A5HJM1 →
P16871 — 0.993 P16871 →
Q4W815 — 0.993 Q4W815 →
Q08501 — 0.992 Q08501 →
O02671 — 0.992 O02671 →
Q62959 — 0.992 Q62959 →
P15260 — 0.992 P15260 →
Q65Z14 — 0.992 Q65Z14 →
Q38IC7 — 0.991 Q38IC7 →
Q99650 — 0.991 Q99650 →
P05710 — 0.991 P05710 →
Q91513 — 0.990 Q91513 →
A0MSX9 — 0.990 A0MSX9 →
Q9D9J7 — 0.990 Q9D9J7 →
Q8K5B1 — 0.990 Q8K5B1 →
Q6PHB0 — 0.989 Q6PHB0 →
Q5XNR9 — 0.989 Q5XNR9 →
P48551 — 0.989 P48551 →
P14787 — 0.988 P14787 →
P16471 — 0.988 P16471 →
Q95LF0 — 0.988 Q95LF0 →
Q28575 — 0.987 Q28575 →
P42703 — 0.987 P42703 →
O46600 — 0.987 O46600 →
O46561 — 0.987 O46561 →
P43432 — 0.987 P43432 →